Mark Cuban Addressed Healthcare Pricing Transparency
Business leaders are using contract analysis tools to bypass opaque pharmacy benefit manager pricing models.
Updated on Sept. 30, 2026 in Healthcare
Live Poll
Should pharmaceutical companies be required to disclose their exact acquisition costs for all medications?
Mark Cuban discussed the need for greater transparency in the U.S. pharmaceutical market during an event at Georgetown University. His remarks focused on how the current industry structure, dominated by pharmacy benefit managers, obscures true drug costs for employers and consumers.
Why it matters
Opaque pricing structures in healthcare often leave businesses unable to verify if they are receiving fair value for drug spending. Cuban argues that trust in the system is eroded by complex intermediary relationships that hide the actual costs paid to manufacturers.
The Mark Cuban Cost Plus Drug Co. utilizes a transparent 15% markup on acquisition costs for all generic drugs. This shift follows historical price surges for medications like Daraprim, which saw its price jump from $7-14 to $750.
The players
Mark Cuban
Entrepreneur and investor who co-founded the Mark Cuban Cost Plus Drug Co. to promote transparent pharmaceutical pricing.
Georgetown University
Academic institution that hosted the discussion on healthcare transparency through its School of Health and Business of Health Initiative.
The details
The Mark Cuban Cost Plus Drug Co. operates by bypassing traditional middlemen, displaying both the acquisition cost and a fixed 15% markup plus shipping to the end user. For employers, this transparency is increasingly sought through the use of AI-driven contract analysis tools designed to strip away hidden financial incentives used by pharmacy benefit managers. These tools allow operators to see through the current model, where a $600 brand drug may only provide $300 in net revenue to the actual manufacturer.
Timeline
Mark Cuban co-founded Cost Plus Drug Co. in 2022.
Mark Cuban spoke at Georgetown University on September 28, 2026.
Market Landscape
The push for pharmacy transparency follows the 2015 Daraprim price increase, which became a focal point for public outcry over generic drug costs. The industry is now seeing a split between traditional, intermediary-heavy models and emerging direct-cost platforms.
Business owners should review their current pharmacy benefit management contracts for hidden fee structures and lack of acquisition cost visibility. Consider utilizing third-party contract analysis tools to identify potential cost savings and improve transparency in employee benefit plans.
The takeaway
The move toward transparent pricing is fundamentally challenging the role of intermediaries in corporate healthcare spend. Operators should audit their pharmacy benefit contracts to determine if they are paying inflated costs that exceed a transparent markup-based model.
Further reading
For more on industry shifts, visit our Healthcare section.
More information
Review pricing transparency information on the Mark Cuban Cost Plus Drug Co portal.
Live Poll
Should pharmaceutical companies be required to disclose their exact acquisition costs for all medications?
